Repatha, evolocumab
Named-patient access overview. Repatha is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
This page is informational, not medical advice.
Ask about Repatha
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Repatha
Repatha (evolocumab) is a fully human IgG2 monoclonal antibody manufactured by Amgen. It binds proprotein convertase subtilisin/kexin type 9 (PCSK9), the circulating protease that targets the low-density lipoprotein receptor (LDLR) on hepatocytes for lysosomal degradation. By neutralizing PCSK9, Repatha extends the lifespan of LDLR on the hepatocyte surface, increases the liver's capacity to clear circulating LDL particles, and drives substantial reductions in LDL cholesterol on top of statin therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Repatha carries US FDA approval to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease; as an adjunct to diet and other LDL-lowering therapies in adults and pediatric patients (10 years and older) with heterozygous familial hypercholesterolemia; as an adjunct to diet and other LDL-lowering therapies in adults and pediatric patients (10 years and older) with homozygous familial hypercholesterolemia; and as an adjunct to diet, alone or in combination with other lipid-lowering therapies, in adults with primary hyperlipidemia to reduce LDL cholesterol.
The FOURIER outcomes trial established that adding Repatha to statin therapy in patients with established cardiovascular disease reduces the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization. The mean on-treatment LDL cholesterol in FOURIER fell to roughly 30 mg/dL, demonstrating that very-low LDL is both achievable and well tolerated for the patient populations studied.
Repatha is supplied as a 140 mg per mL single-use prefilled SureClick autoinjector, a single-use prefilled syringe, and a 420 mg per 3.5 mL single-use Pushtronex on-body infusor for once-monthly administration. All presentations require refrigerated storage at 2 to 8 degrees Celsius in the original carton, and unopened product may be kept at room temperature up to 25 degrees Celsius for up to thirty days before use.
How Reserve Meds coordinates Repatha
- Patient or treating physician submits a named-patient request through the Patient Portal.
- Clinical team verifies appropriateness of Repatha for the patient's lipid profile, cardiovascular risk, and destination country.
- Treating physician issues a prescription with clinical justification, lipid panel, and statin-history record.
- Country-specific named-patient or personal-import documentation is prepared in the destination language.
- Repatha is sourced from a US-licensed pharmaceutical wholesale partner with full serialized traceability.
- Validated cold-chain shipment is coordinated to the patient's physician or hospital pharmacy.
- A named coordinator stays with the case from intake through delivery confirmation.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list evolocumab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Repatha in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Indications, in brief
Established cardiovascular disease. In adults with prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease who are on maximally tolerated statin therapy and still have residual LDL cholesterol elevation, Repatha reduces the risk of recurrent atherothrombotic events. The clinical benefit is consistent across baseline LDL levels and extends to very-low achieved LDL values.
Heterozygous familial hypercholesterolemia (HeFH). HeFH is an autosomal-dominant disorder of LDL clearance, most commonly driven by pathogenic variants in LDLR, APOB, or PCSK9, with prevalence estimated at roughly one in 250 worldwide. Lifelong LDL exposure produces early-onset atherosclerotic cardiovascular disease. Repatha added to statins and ezetimibe further reduces LDL cholesterol and lifetime cardiovascular risk in adults and pediatric patients ten years and older.
Homozygous familial hypercholesterolemia (HoFH). HoFH is a rare and severe form, with very high LDL cholesterol from birth and accelerated atherosclerosis in childhood and early adulthood. Repatha reduces LDL cholesterol in HoFH patients who retain residual LDLR function, complementing other therapies such as statins, ezetimibe, lipoprotein apheresis, and lomitapide where appropriate.
Primary hyperlipidemia. In adults with primary hyperlipidemia who are not at LDL goal on maximally tolerated statin therapy, or who are statin-intolerant, Repatha provides an additional LDL reduction of approximately 55 to 60 percent versus placebo, on top of background lipid therapy.
What every destination country asks for
Documentation we prepare always covers the same medical core: physician letter of medical necessity tied to the labeled indication, recent lipid panel including LDL cholesterol, statin and ezetimibe history with dose and duration, documentation of statin intolerance where claimed, cardiovascular risk profile and any prior atherosclerotic events, family history and genetic confirmation for familial hypercholesterolemia where available, the prescription itself with strength and quantity, and the country-specific named-patient or personal-import application translated into the destination language.
Cold-chain and handling
Every Repatha presentation in our supply chain travels under a validated 2 to 8 degree Celsius cold-chain with continuous temperature logging from the US wholesaler to the destination physician or pharmacy. Hand-off is documented with the temperature record, lot and serial number, and chain-of-custody signature. The label-allowed room-temperature window of up to thirty days at or below 25 degrees Celsius is preserved as buffer at the destination, not consumed in transit.
Start a request for Repatha
Send us the medicine and your country. We reply within one business day with case-specific feasibility, an indicative timeline, and a formal written quote.
Ask about a medicine Or message us on WhatsApp
Reserved for you.
Frequently asked questions
How can I get Repatha if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Repatha for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Repatha through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Repatha. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Repatha through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Repatha to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Repatha to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Repatha cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Repatha?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.